Table 1.
Demographic and clinical characteristics of SLE patients and control group
| SLE patients (n = 34) | Control group (n = 31) | |
|---|---|---|
| Age (years) | 36.9 ± 11.8 | 31.2 ± 4.5 |
| Gender | ||
| Female | 31 (91.2 %) | 27 (87.1 %) |
| Male | 3 (8.8 %) | 4 (12.9 %) |
| Smoker | 4 (11.8 %) | 0 (0 %) |
| Disease duration (years) | 8.9 ± 11.2 | |
| SLAM score median (range) | 8 (3–15) | |
| Active | 6 (17.7 %) | |
| Inactive | 28 (82.3 %) | |
| ANA ≥1:160 | 34 (100 %) | |
| P/MP therapy | 16 (47 %) | |
| NSAID therapy | 9 (26.5 %) | |
| Immunosuppressive (MM, A) therapy | 4 (11.8 %) |
A azathioprine, ANA antinuclear antibody, MM mycophenolate mofetil, MP methylprednisolone, NSAID non-steroidal anti-inflammatory drug, P prednisone, SLAM systemic lupus activity measure